Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02152345 · ClinicalTrials.gov registry record · Phase 4
Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients
A Phase 4 study of Implant or Graft; Rejection, sponsored by Columbia University.
- Completed
- Registry status
- Phase 4
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT02152345 is a Phase 4 study of Implant or Graft; Rejection that has completed, run by Columbia University. The registered enrollment target is 57 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02152345, a Phase 4 study of Implant or Graft; Rejection, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to find out whether treatment to prevent kidney rejection with belatacept in presence of Thymoglobulin induction and withdrawal of steroids will result in less delayed graft function or "sleepy kidney" after transplant than that seen in patients who get tacrolimus as their main drug to prevent rejection instead of belatacept. The investigators will also look at whether patients who get belatacept have the same, lesser or more problems that those who get tacrolimus.
Conditions Studied
Interventions
- DRUG Methylprednisolone
- DRUG Tacrolimus
- DRUG Belatacept
- DRUG Mycophenolate
- DRUG rATG
Study Locations (1)
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02152345
The ClinicalTrials.gov registry entry for NCT02152345 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Implant or Graft; Rejection appearing as the primary indexed condition, and to 5 interventions - of which Methylprednisolone is the first listed.
NCT02152345 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02152345 about?
NCT02152345 is a clinical study titled "Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients". The main purpose of this study is to find out whether treatment to prevent kidney rejection with belatacept in presence of Thymoglobulin induction and withdrawal of steroids will result in less delayed graft function or "sleepy kidney" after transplant than that seen in patients who get tacrolimus as...
What is the current status of trial NCT02152345?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 57 participants. The study started on 2014-06. Estimated completion is 2016-12-31.
What conditions does trial NCT02152345 study?
This clinical trial studies the following conditions: Implant or Graft; Rejection.
What interventions are being tested in trial NCT02152345?
The interventions under investigation include: Methylprednisolone (DRUG), Tacrolimus (DRUG), Belatacept (DRUG), Mycophenolate (DRUG), rATG (DRUG).
Who is sponsoring clinical trial NCT02152345?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02152345 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.